Bioventus received ANVISA approval to market DUROLANE® single-injection in Brazil to treat hip osteoarthritis.
Pfizer, Bioventus’ choice of exclusive distribution partner, has >100 sales representatives throughout Brazil and will offer DUROLANE as part of a pain management portfolio alongside the NSAID CELEBRA®.
Bioventus entered into a definitive agreement to divest its next-generation bone morphogenetic protein development program to Viscogliosi Brothers in early 3Q18. The shift allows Bioventus to focus resources in support of its osteoarthritis, surgical and non-surgical bone healing portfolios (e.g. SUPARTZ, DUROLANE and the EXOGEN ultrasound bone healing product);
Bioventus received ANVISA approval to market DUROLANE® single-injection in Brazil to treat hip osteoarthritis.
Pfizer, Bioventus' choice of exclusive distribution partner, has >100 sales representatives throughout Brazil and will offer DUROLANE as part of a pain management portfolio alongside the NSAID CELEBRA®.
Bioventus entered into a...
Bioventus received ANVISA approval to market DUROLANE® single-injection in Brazil to treat hip osteoarthritis.
Pfizer, Bioventus’ choice of exclusive distribution partner, has >100 sales representatives throughout Brazil and will offer DUROLANE as part of a pain management portfolio alongside the NSAID CELEBRA®.
Bioventus entered into a definitive agreement to divest its next-generation bone morphogenetic protein development program to Viscogliosi Brothers in early 3Q18. The shift allows Bioventus to focus resources in support of its osteoarthritis, surgical and non-surgical bone healing portfolios (e.g. SUPARTZ, DUROLANE and the EXOGEN ultrasound bone healing product);
Copy to clipboard 
